Ceptur Therapeutics, Inc.., a Hillsborough, New Jersey-based biotechnology company focused on developing targeted oligonucleotide therapeutics based on U1 Adaptor technology, closed a $75M Series A financing.
The round was co-led by venBio Partners and Qiming Venture Partners USA with participation from Perceptive Xontogeny Venture (PXV) Fund, Bristol Myers Squibb and Janus Henderson Investors and existing investors Affinity Asset Advisors, Boxer Capital and LifeSci Venture Partners. In conjunction with the funding, Aaron Royston, M.D., M.B.A., Managing Partner at venBio Partners, and Colin Walsh, Ph.D., Partner at Qiming Venture Partners USA, joined Cepturās Board of Directors.
Led by co-founder, President and CEO P. Peter Ghoroghchian, MD, PhD., Ceptur Therapeutics is a pre-clinical stage biotechnology company focused on developing targeted oligonucleotide therapeutics based on U1 Adaptor technology. U1 Adaptors are bivalent oligonucleotides that engage sequence-specific mRNA and the U1 small nuclear ribonuclear protein (U1 snRNP), which is a ubiquitous intracellular machine that regulates transcription and splicing. U1 Adaptor therapeutics control gene expression at the pre-mRNA level within the nucleus, affording advantageous properties for drugging difficult targets.
FinSMEs
20/01/2022